{"nctId":"NCT00225017","briefTitle":"Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study","startDateStruct":{"date":"2005-06"},"conditions":["HIV Infection","Hyperlipidemia"],"count":50,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: Atazanavir"]},{"label":"B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: current antiretroviral regimen"]}],"interventions":[{"name":"Atazanavir","otherNames":["Reyataz"]},{"name":"current antiretroviral regimen","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HIV infection\n* HIV-1 RNA \\< 500 copies/ml\n* Fasting LDL cholesterol \\>130 mg/dl OR fasting triglycerides \\>200 mg/dl\n* CD4 count \\>100 cells/mm\n* Stable antiretroviral regimen for at least 12 weeks prior to study entry that includes a protease inhibitor (PI) with or without ritonavir boosting\n\nExclusion Criteria:\n\n* History of heart disease, uncontrolled hypertension, peripheral vascular disease\n* Current non-nucleoside reverse transcriptase inhibitor (NNRTI) in the PI-containing regimen within 4 weeks\n* Prior or current use of atazanavir\n* Initiation of treatment with lipid-lowering drugs within 4 weeks prior to study entry","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Change in Brachial Artery Flow Mediated (FMD) Vasodilation Between Arms From Baseline to Week 24","description":"Brachial artery reactivity assessed by noninvasively measuring brachial artery diameter and flow velocities in response to overinflated blood pressure cuff (Flow mediated dilation (FMD))in subjects switching to atazanavir and in subjects continuing on a stable antiretroviral regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.14","spread":null},{"groupId":"OG001","value":"0.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol Levels From Baseline to Week 24","description":"Total cholesterol level changes within and between arms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in LDL Particle Number From Baseline to Week 24","description":"Change in LDL particle number","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-194","spread":null},{"groupId":"OG001","value":"-116","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":[]}}}